Researchers at the University of Cambridge, Spanish National Cancer Research Centre (CNIO), and biotech startup Tailor Bio have developed an innovative genomic assay capable of forecasting cancer patient resistance to platinum, anthracycline, and taxane chemotherapies. This test analyzes chromosomal instability signatures within tumors to guide personalized therapy, potentially avoiding ineffective and toxic treatment courses. Retrospective validation encompassed data from 840 patients across cancer types, marking a significant stride in precision oncology.